Join to view full profile
3400 Spruce St1 Maloney BuildingPhiladelphia, PA 19104
Phone+1 215-662-3957
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 1 invite waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Roland Knoblauch, MD is an oncologist in Philadelphia, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania.
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2004 - 2007
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2001 - 2004
New York University School of MedicineClass of 2001
Certifications & Licensure
PA State Medical License 2004 - 2026
Publications & Presentations
PubMed
- 22 citationsAmivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A.Benjamin Besse, Koichi Goto, Yongsheng Wang, Se-Hoon Lee, Melina E Marmarelis
Journal of Thoracic Oncology. 2025-05-01 - 261 citationsAmivantamab plus Lazertinib in Previously Untreated-Mutated Advanced NSCLC.Byoung C Cho, Shun Lu, Enriqueta Felip, Alexander I Spira, Nicolas Girard
The New England Journal of Medicine. 2024-10-24 - 6 citationsDetermination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non-Small Cell Lung Cancer.Nahor Haddish-Berhane, Yaming Su, Alberto Russu, Meena Thayu, Roland E Knoblauch
Clinical Pharmacology and Therapeutics. 2024-03-01
Press Mentions
FDA Approves Yondelis for Two Common Subtypes of Soft Tissue SarcomaOctober 26th, 2015
